Form 4: Alnylam Pharmaceuticals Director David E.I. Pyott Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director David E.I. Pyott exercised stock options and sold shares of Alnylam Pharmaceuticals common stock on June 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 24, 2024, David E.I. Pyott, a director of Alnylam Pharmaceuticals, executed stock options to acquire shares of common stock at prices of $70.2, $71.99, and $88.95.
• Pyott then sold 17,560 shares at $220, 7,420 shares at $221, and 7,470 shares at $222.
• These transactions were conducted under a Rule 10b5-1(c) trading plan adopted on August 11, 2023.
• Following these transactions, Pyott directly owns 136 shares and indirectly owns 27,900 shares through a trust.
• He also directly owns derivative securities including 3,830 stock options exercisable at $70.2, 3,780 stock options exercisable at $71.99, and 7,440 stock options exercisable at $88.95.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, which is important for maintaining investor confidence. The use of a 10b5-1 trading plan suggests that these transactions were pre-planned and not based on any material non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates